Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies
Scenario 1: Priority Review Granted (Q3 2027) BLA submitted: Q1 2027 FDA accepts filing: ~2 months later Priority review: ~6 months from acceptance PDUFA date / approval: Q3 2027 Launch: Q4 2027 Scenario 2: Standard Review (Most Likely Q1Q2 2028) BLA submitted: Q1 2027 FDA accepts filing: ~2 months later Standard review: 1012 months from acceptance PDUFA date / approval: Q1Q2 2028 Launch: Q2Q3 2028 Scenario 3: Complete Response Letter or Delays (Late 2028 or Beyond) Potential causes: an unexpected safety signal emerging during review, manufacturing or facility inspection issues, or the FDA requesting additional data via a Complete Response Letter
For example, gastro-oesophageal reflux disease (GORD) is listed as a common side effect (affecting up to 1 in 10 people) with semaglutide (Wegovy), while dyspepsia (indigestion) is common with several agents in this class
The medication targets the GLP-1, GIP, and glucagon receptors, which is why its often described as a triple hormone receptor agonist
Get Your Medication If approved, your medication ships within 2 business days
Retatrutide remains under investigation in clinical trials, and its safety, efficacy, and potential applications are not yet fully understood